Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369889 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer
A Phase 2 study of Thymoma and Thymic Cancer, sponsored by Indiana University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00369889 is a Phase 2 study of Thymoma and Thymic Cancer that has completed, run by Indiana University School of Medicine. The registered enrollment target is 18 participants, below the 142-participant average among 9 other Thymoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00369889, a Phase 2 study of Thymoma and Thymic Cancer, has completed, sponsored by Indiana University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the rate of response with the combination of erlotinib and bevacizumab in previously treated patients with thymoma or thymic carcinoma, and to determine potential molecular markers that may predict response to therapy in patients with thymoma or thymic carcinoma.
Conditions Studied
Interventions
- DRUG bevacizumab
- DRUG Erlotinib
Study Locations (1)
Indiana
- Indiana University Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369889
The ClinicalTrials.gov registry entry for NCT00369889 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 9 other Thymoma trials with a reported enrollment target (87% lower). The listed sponsor is Indiana University School of Medicine, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Thymoma appearing as the primary indexed condition, and to 2 interventions - of which bevacizumab is the first listed.
NCT00369889 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT00369889 about?
NCT00369889 is a clinical study titled "A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer". The purpose of this study is to determine the rate of response with the combination of erlotinib and bevacizumab in previously treated patients with thymoma or thymic carcinoma, and to determine potential molecular markers that may predict response to therapy in patients with thymoma or thymic carci...
What is the current status of trial NCT00369889?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2006-08. Estimated completion is 2007-09.
What conditions does trial NCT00369889 study?
This clinical trial studies the following conditions: Thymoma, Thymic Cancer.
What interventions are being tested in trial NCT00369889?
The interventions under investigation include: bevacizumab (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00369889?
This trial is sponsored by Indiana University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00369889 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thymoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
RECRUITING · Phase 2
-
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
-
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
COMPLETED · Phase 2
-
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RECRUITING
-
An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.